THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA
Thalidomide is a therapeutic option for patients with β-thalassemia by increasing fetal hemoglobin and thereby reducing the requirement for blood transfusions. However, information on changes in erythropoiesis and iron homeostasis during thalidomide treatment is lacking. This study investigated the...
Saved in:
Main Authors: | Kun Yang, Jian Xiao |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2024-01-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Online Access: | https://mjhid.org/mjhid/article/view/5416 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ineffective Erythropoiesis in β-Thalassemia
by: Jean-Antoine Ribeil, et al.
Published: (2013-01-01) -
𝛽-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload
by: Luca Melchiori, et al.
Published: (2010-01-01) -
EFFECTS OF THALIDOMIDE ON ENDOTHELIAL ACTIVATION AND STRESS INDEX IN CHILDREN WITH Β-THALASSEMIA MAJOR
by: Kun Yang
Published: (2024-10-01) -
CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES?
by: Vincenzo De Sanctis, et al.
Published: (2024-01-01) -
Crosstalk between Erythropoiesis and Iron Metabolism
by: Stefano Rivella, et al.
Published: (2010-01-01)